{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T20:00:03Z","timestamp":1765742403964},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.cmi.2016.03.006","type":"journal-article","created":{"date-parts":[[2016,4,28]],"date-time":"2016-04-28T00:12:42Z","timestamp":1461802362000},"page":"S103-S112","source":"Crossref","is-referenced-by-count":29,"special_numbering":"S5","title":["Can we control all-cause meningococcal disease in Europe?"],"prefix":"10.1016","volume":"22","author":[{"given":"M.","family":"Sadarangani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.J.","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2016.03.006_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul Health Metr"},{"key":"10.1016\/j.cmi.2016.03.006_bib2","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0950268800066449","article-title":"The stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica","volume":"99","author":"Cartwright","year":"1987","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.cmi.2016.03.006_bib3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-1-61779-346-2_2","article-title":"Classification and pathogenesis of meningococcal infections","volume":"799","author":"Brandtzaeg","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.cmi.2016.03.006_bib4","series-title":"Handbook of meningococcal disease management","first-page":"25","article-title":"Pathogenesis of invasive disease","author":"Ovstebo","year":"2016"},{"issue":"Suppl.\u00a02","key":"10.1016\/j.cmi.2016.03.006_bib5","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2011.12.062","article-title":"Meningococcal disease: clinical presentation and sequelae","volume":"30","author":"Pace","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2016.03.006_bib6","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1136\/adc.2007.131862","article-title":"Long-term skin scarring and orthopaedic sequelae in survivors of meningococcal septic shock","volume":"94","author":"Buysse","year":"2009","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.cmi.2016.03.006_bib7","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/01.CCM.0000299740.65484.CA","article-title":"Surviving meningococcal septic shock: health consequences and quality of life in children and their parents up to 2 years after pediatric intensive care unit discharge","volume":"36","author":"Buysse","year":"2008","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cmi.2016.03.006_bib8","doi-asserted-by":"crossref","first-page":"R124","DOI":"10.1186\/cc9087","article-title":"Surviving meningococcal septic shock in childhood: long-term overall outcome and the effect on health-related quality of life","volume":"14","author":"Buysse","year":"2010","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2016.03.006_bib9","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/INF.0000000000000282","article-title":"The clinical features and long term sequelae of invasive meningococcal disease in children","volume":"33","author":"Stein-Zamir","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2016.03.006_bib10","doi-asserted-by":"crossref","first-page":"e502","DOI":"10.1542\/peds.2008-0581","article-title":"Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study","volume":"123","author":"Borg","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.cmi.2016.03.006_bib11","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1007\/s00134-002-1237-2","article-title":"Psychiatric adjustment following meningococcal disease treated on a PICU","volume":"28","author":"Judge","year":"2002","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2016.03.006_bib12","first-page":"3","article-title":"Late sequelae after meningococcal disease. A controlled study in young men","volume":"7","author":"Sander","year":"1984","journal-title":"NIPH Ann"},{"key":"10.1016\/j.cmi.2016.03.006_bib13","series-title":"Bacterial meningitis and meningococcal septicaemia: management of bacterial meningitis and meningococcal septicaemia in children and young people younger than 16 years in primary and secondary care","author":"National Collaborating Centre for Women\u2019s and Children\u2019s Health","year":"2010"},{"key":"10.1016\/j.cmi.2016.03.006_bib14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(06)67932-4","article-title":"Clinical recognition of meningococcal disease in children and adolescents","volume":"367","author":"Thompson","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2016.03.006_bib15","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s10096-008-0535-1","article-title":"Pre-admission clinical course of meningococcal disease and opportunities for the earlier start of appropriate intervention: a prospective epidemiological study on 752 patients in the Netherlands, 2003\u20132005","volume":"27","author":"de Greeff","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2016.03.006_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1741-7015-7-47","article-title":"Sequelae due to bacterial meningitis among African children: a systematic literature review","volume":"7","author":"Ramakrishnan","year":"2009","journal-title":"BMC Med"},{"key":"10.1016\/j.cmi.2016.03.006_bib17","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/adc.85.5.386","article-title":"Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery","volume":"85","author":"Booy","year":"2001","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.cmi.2016.03.006_bib18","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/adc.85.5.382","article-title":"Mortality in severe meningococcal disease","volume":"85","author":"Thorburn","year":"2001","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.cmi.2016.03.006_bib19","series-title":"Nelson textbook of pediatrics","first-page":"1356","article-title":"Neisseria meningitidis (meningococcus)","author":"Sadarangani","year":"2016"},{"key":"10.1016\/j.cmi.2016.03.006_bib20","series-title":"ECDC surveillance report. Surveillance of invasive bacterial diseases in Europe, 2012. Invasive pneumococcal disease, invasive Haemophilus influenzae disease and invasive meningococcal disease","author":"Ciaravino","year":"2015"},{"key":"10.1016\/j.cmi.2016.03.006_bib21","series-title":"Invasive Neisseria meningitidis in Europe, 2006","author":"Ramsay","year":"2007"},{"key":"10.1016\/j.cmi.2016.03.006_bib22","series-title":"ECDC surveillance report. Annual epidemiological report, 2014. Vaccine-preventable diseases\u2014invasive bacterial diseases","author":"Albu","year":"2015"},{"key":"10.1016\/j.cmi.2016.03.006_bib23","doi-asserted-by":"crossref","first-page":"g5725","DOI":"10.1136\/bmj.g5725","article-title":"Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study","volume":"349","author":"Christensen","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2016.03.006_bib24","doi-asserted-by":"crossref","first-page":"e003312","DOI":"10.1136\/bmjopen-2013-003312","article-title":"Association between population prevalence of smoking and incidence of meningococcal disease in Norway, Sweden, Denmark and the Netherlands between 1975 and 2009: a population-based time series analysis","volume":"4","author":"Norheim","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.cmi.2016.03.006_bib25","series-title":"Health protection report, weekly report: continuing increase in meningococcal group W (MenW) disease in England","author":"Public Health England","year":"2015"},{"key":"10.1016\/j.cmi.2016.03.006_bib26","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/cid\/ciu881","article-title":"Increase in endemic Neisseria meningitidis capsular group w sequence type 11 complex associated with severe invasive disease in England and Wales","volume":"60","author":"Ladhani","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"28","key":"10.1016\/j.cmi.2016.03.006_bib27","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES2015.20.28.21188","article-title":"Targeted vaccination of teenagers following continued rapid endemic expansion of a single meningococcal group w clone (sequence type 11 clonal complex), United Kingdom, 2015","volume":"20","author":"Campbell","year":"2015","journal-title":"Euro Surveill"},{"key":"10.1016\/j.cmi.2016.03.006_bib28","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0140-6736(85)90224-7","article-title":"Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide a vaccine","volume":"2","author":"Reingold","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2016.03.006_bib29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1128\/CDLI.11.1.83-88.2004","article-title":"Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A\/C polysaccharide vaccination in Saudi Arabia","volume":"11","author":"Jokhdar","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.cmi.2016.03.006_bib30","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1086\/515346","article-title":"Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination","volume":"178","author":"Granoff","year":"1998","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2016.03.006_bib31","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJM197709292971302","article-title":"Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age","volume":"297","author":"Peltola","year":"1977","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2016.03.006_bib32","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1172\/JCI108235","article-title":"Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants","volume":"56","author":"Gold","year":"1975","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cmi.2016.03.006_bib33","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM197002192820803","article-title":"Prevention of meningococcal disease by group C polysaccharide vaccine","volume":"282","author":"Artenstein","year":"1970","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2016.03.006_bib34","series-title":"Handbook of meningococcal disease: infection biology, vaccination, clinical management","article-title":"Conjugate vaccines","author":"Ravenscoft","year":"2006"},{"key":"10.1016\/j.cmi.2016.03.006_bib35","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","article-title":"Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction","volume":"364","author":"Trotter","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2016.03.006_bib36","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.cmi.2016.03.006_bib37","doi-asserted-by":"crossref","first-page":"A97","DOI":"10.1016\/j.vaccine.2007.04.049","article-title":"The meningitis vaccine project","volume":"25","author":"LaForce","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2016.03.006_bib38","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(13)61612-8","article-title":"Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]","volume":"383","author":"Daugla","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2016.03.006_bib39","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/1471-2334-13-363","article-title":"Phenotypic and genotypic characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup A conjugate vaccine","volume":"13","author":"Kristiansen","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2016.03.006_bib40","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2016.03.006_bib41","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1084\/jem.138.5.1156","article-title":"Release of endotoxin in the form of cell wall blebs during in\u00a0vitro growth of Neisseria meningitidis","volume":"138","author":"Devoe","year":"1973","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.cmi.2016.03.006_bib42","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1128\/IAI.66.10.4755-4761.1998","article-title":"Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine","volume":"66","author":"Milagres","year":"1998","journal-title":"Infect Immun"},{"key":"10.1016\/j.cmi.2016.03.006_bib43","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1128\/CVI.13.4.486-491.2006","article-title":"The VR2 epitope on the PorA p1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB","volume":"13","author":"Martin","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.cmi.2016.03.006_bib44","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1128\/IAI.63.12.4642-4652.1995","article-title":"Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine","volume":"63","author":"Rosenqvist","year":"1995","journal-title":"Infect Immun"},{"key":"10.1016\/j.cmi.2016.03.006_bib45","first-page":"195","article-title":"Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba","volume":"14","author":"Sierra","year":"1991","journal-title":"NIPH Ann"},{"key":"10.1016\/j.cmi.2016.03.006_bib46","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1473-3099(11)70027-5","article-title":"From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak","volume":"11","author":"Caron","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"1200","key":"10.1016\/j.cmi.2016.03.006_bib47","first-page":"1","article-title":"Proceedings of the Meningococcal Vaccine Strategy World Health Organization satellite meeting, 10 March 2004, Auckland, New Zealand","volume":"117","author":"Sexton","year":"2004","journal-title":"N\u00a0Z Med J"},{"key":"10.1016\/j.cmi.2016.03.006_bib48","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1128\/IAI.66.7.3223-3231.1998","article-title":"Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial","volume":"66","author":"Wedege","year":"1998","journal-title":"Infect Immun"},{"key":"10.1016\/j.cmi.2016.03.006_bib49","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0264-410X(02)00591-1","article-title":"Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease","volume":"21","author":"Holst","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2016.03.006_bib50","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0264-410X(94)00037-N","article-title":"Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease","volume":"13","author":"Boslego","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2016.03.006_bib51","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/ije\/24.5.1050","article-title":"Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case\u2013control study","volume":"24","author":"Noronha","year":"1995","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.cmi.2016.03.006_bib52","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/0140-6736(92)93086-3","article-title":"Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil","volume":"340","author":"de Moraes","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2016.03.006_bib53","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1586\/14760584.2015.1016915","article-title":"Neisseria meningitidis factor H\u2013binding protein fHbp: a key virulence factor and vaccine antigen","volume":"14","author":"Seib","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.cmi.2016.03.006_bib54","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4161\/hv.23222","article-title":"Potential impact of the bivalent rLP2806 vaccine on Neisseria meningitidis carriage and invasive serogroup B disease","volume":"9","author":"Anderson","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.cmi.2016.03.006_bib55","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/infdis\/jit239","article-title":"Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H\u2013binding protein vaccines","volume":"208","author":"Konar","year":"2013","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2016.03.006_bib56","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40265-013-0155-7","article-title":"A\u00a0multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program","volume":"74","author":"O\u2019Ryan","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.cmi.2016.03.006_bib57","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1073\/pnas.0915162107","article-title":"Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans","volume":"107","author":"Serruto","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cmi.2016.03.006_bib58","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.vaccine.2009.12.082","article-title":"Influence of serogroup B meningococcal vaccine antigens on growth and survival of the meningococcus in\u00a0vitro and in ex\u00a0vivo and in\u00a0vivo models of infection","volume":"28","author":"Seib","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2016.03.006_bib59","doi-asserted-by":"crossref","first-page":"17128","DOI":"10.1073\/pnas.1419686111","article-title":"Structure of the meningococcal vaccine antigen NadA and epitope mapping of a bactericidal antibody","volume":"111","author":"Malito","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cmi.2016.03.006_bib60","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2016.03.006_bib61","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2016.03.006_bib62","doi-asserted-by":"crossref","first-page":"E715","DOI":"10.1503\/cmaj.130257","article-title":"Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose","volume":"185","author":"Snape","year":"2013","journal-title":"CMAJ"},{"key":"10.1016\/j.cmi.2016.03.006_bib63","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1016\/j.vaccine.2015.06.011","article-title":"Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults","volume":"33","author":"Nolan","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2016.03.006_bib64","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/adc.2009.180596","article-title":"Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers","volume":"96","author":"Jackson","year":"2011","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.cmi.2016.03.006_bib65","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1542\/peds.2014-4015","article-title":"First use of a serogroup B meningococcal vaccine in the US in response to a university outbreak","volume":"135","author":"McNamara","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.cmi.2016.03.006_bib66","first-page":"544","article-title":"Genomic resolution of an aggressive, widespread, diverse and expanding meningococcal serogroup B, C and W lineage","volume":"71","author":"Lucidarme","year":"2015","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.cmi.2016.03.006_bib67","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2016.03.006_bib68","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2016.03.006_bib69","doi-asserted-by":"crossref","DOI":"10.4161\/hv.28666","article-title":"A\u00a0phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I): efects of prophylactic paracetamol on immunogenicity and reactogenicity of routine infant vaccines and 4CMenB","volume":"10","author":"Prymula","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.cmi.2016.03.006_bib70","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1016\/j.vaccine.2014.07.049","article-title":"A\u00a0randomized, phase 1\/2 trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants","volume":"32","author":"Martinon-Torres","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2016.03.006_bib71","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1586\/14760584.2015.1015997","article-title":"Neisseria meningitidis serogroup B bivalent factor H binding protein vaccine","volume":"14","author":"Brendish","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.cmi.2016.03.006_bib72","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4049\/jimmunol.3.3.201","article-title":"The relation of the meningococcidal activity of the blood to resistance to virulent meningococci","volume":"3","author":"Matsunami","year":"1918","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.cmi.2016.03.006_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4049\/jimmunol.7.1.1","article-title":"A\u00a0study of the virulence of meningococci for man and of human susceptibility to meningococcic infection","volume":"7","author":"Heist","year":"1922","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.cmi.2016.03.006_bib74","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.cmi.2016.03.006_bib75","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2014serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2016.03.006_bib76","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1128\/IAI.62.10.4419-4424.1994","article-title":"Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy","volume":"62","author":"Milagres","year":"1994","journal-title":"Infect Immun"},{"key":"10.1016\/j.cmi.2016.03.006_bib77","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines","volume":"107","author":"Donnelly","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cmi.2016.03.006_bib78","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.vaccine.2015.04.015","article-title":"Mats: global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine","volume":"33","author":"Medini","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2016.03.006_bib79","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1016\/j.vaccine.2009.01.075","article-title":"Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide","volume":"27","author":"McNeil","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2016.03.006_bib80","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bmj.326.7385.365","article-title":"Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis","volume":"326","author":"Ramsay","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2016.03.006_bib81","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(02)08679-8","article-title":"Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination","volume":"359","author":"Maiden","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2016.03.006_bib82","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2016.03.006_bib83","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1093\/cid\/ciu597","article-title":"The impact of the meningococcal serogroup C conjugate vaccine in Canada between 2002 and 2012","volume":"59","author":"Sadarangani","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2016.03.006_bib84","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial","volume":"384","author":"Read","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2016.03.006_bib85","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.4161\/hv.25505","article-title":"Persistence of antibodies in adolescents 18\u201324 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine","volume":"9","author":"Santolaya","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.cmi.2016.03.006_bib86","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2016.03.006_bib87","series-title":"JCVI position statement on use of Bexsero meningococcal B vaccine in the uk","author":"Joint Committee on Vaccination and Immunisation","year":"2014"},{"key":"10.1016\/j.cmi.2016.03.006_bib88","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.vaccine.2013.03.034","article-title":"Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact","volume":"31","author":"Christensen","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2016.03.006_bib89","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1016\/j.vaccine.2014.07.096","article-title":"Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada","volume":"32","author":"Tu","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2016.03.006_bib90","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.4161\/hv.23888","article-title":"Cost-effectiveness of vaccination against meningococcal B among Dutch infants: crucial impact of changes in incidence","volume":"9","author":"Pouwels","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.cmi.2016.03.006_bib91","doi-asserted-by":"crossref","first-page":"e0123383","DOI":"10.1371\/journal.pone.0123383","article-title":"Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme","volume":"10","author":"Tirani","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2016.03.006_bib92","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/21645515.2015.1010885","article-title":"Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country","volume":"11","author":"Izquierdo","year":"2015","journal-title":"Hum Vaccin Immunother"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X16300210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X16300210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T01:27:16Z","timestamp":1718501236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X16300210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":92,"alternative-id":["S1198743X16300210"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2016.03.006","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}